QDII投资额度持续放宽 “港股+医药”成资金新锚点

Group 1 - The QDII (Qualified Domestic Institutional Investor) investment quota is being expanded, leading to increased enthusiasm for investing in Hong Kong stocks, particularly in the innovative pharmaceutical sector [1][2] - Multiple QDII products have reported returns exceeding 50% year-to-date, with a notable focus on the Hong Kong pharmaceutical sector, indicating strong recognition of the "innovative drugs + Hong Kong stocks" combination [1][3] - The innovative drug industry is transitioning from a speculative phase to a critical point of commercial model realization, supported by policy benefits, accelerated overseas expansion, and enhanced global competitiveness [1][4] Group 2 - As of June 27, the total number of QDII funds reached 312, accounting for approximately 2.42% of all public funds, with a total net asset value of 582 billion yuan [2] - Recent QDII fund issuances have focused on popular themes such as healthcare, technology, and consumption, with several new funds exceeding 1 billion yuan in issuance scale [2][3] - The Hong Kong pharmaceutical sector has shown significant rebound, contributing to substantial excess returns for related QDII products, with some funds reporting returns as high as 89.15% [3][4] Group 3 - Fund companies are highlighting the mid-term investment value of the innovative drug sector, despite potential short-term volatility risks, suggesting that the sector is not merely a short-term speculative play [4][5] - The innovative drug sector is viewed as having high mid-term investment value, with opportunities for strategic positioning during market corrections [5][6] - The Hong Kong market is expected to benefit from new consumption models and has a diverse range of quality assets in sectors like AI, semiconductors, and innovative drugs, making it attractive for long-term investment [6]